Clinical Trial ProgressThe interim data for the trial demonstrated a remarkable >60% complete response rate, indicating significant potential for a non-invasive alternative to Mohs surgery.
Financial StabilityThe company has a pro-forma cash balance of $10.8 million, providing financial runway until the second half of 2025 through interim and full Phase 2 trial data.
Market OpportunityNodular basal cell carcinoma affects approximately 3 million patients annually in the US, presenting a significant market opportunity for SkinJect.